Hepatic ABC transporters and triglyceride metabolism

Current Opinion in Lipidology

Volumn 23, Issue 3, 2012, Pages 196-200

  Parks, John S ^a   Chung, Soonkyu ^b   Shelness, Gregory S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

ATP binding cassette transporter A1; high density lipoprotein formation; mRNA; Tangier disease; very low density lipoprotein production

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; MICRORNA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

FATTY ACID OXIDATION; GENE EXPRESSION; HUMAN; LIPID METABOLISM; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; LIVER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TANGIER DISEASE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; GENETIC VARIATION; HUMANS; LIVER; MICRORNAS; TRIGLYCERIDES;

MUS; PRIMATES;

EID: 84861094609     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328352dd1a     Document Type: Review

References (33)

1. Assman G, von Eckardstein A, Brewer HB Jr. Familial analphalipoproteinemia: Tangier disease. 8th ed. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Volkman BF (editors). The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. pp. 2937-2960.
2. Clee SM, Kastelein JJP, Van Dam M, et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 hetero-zygotes. J Clin Invest 2000; 106:1263-1270.
3. Kolovou G, Daskalova D, Anagnostopoulou K, et al. Postprandial hypertrigly-ceridaemia in patients with Tangier disease. J Clin Pathol 2003; 56:937-941. (Pubitemid 37533238)
4. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56:45-62. (Pubitemid 40299773)
5. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106:453-458. (Pubitemid 30666377)
6. Adiels M, Olofsson SO, Taskinen MR, et al. Diabetic dyslipidaemia. Curr Opin Lipidol 2006; 17:238-246. (Pubitemid 43786057)
7. Adiels M, Boren J, Caslake MJ, et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005; 25:1697-1703. (Pubitemid 41098943)
8. Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arter-ioscler Thromb Vasc Biol 2003; 23:160-167. (Pubitemid 36231923)
9. Tall AR, Small DM. Body cholesterol removal: role of plasma high-density lipoproteins. Adv Lipid Res 1980; 17:1-51.
10. Sahoo D, Trischuk TC, Chan T, et al. ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes. J Lipid Res 2004; 45:1122-1131. (Pubitemid 38679508)
11. Chung S, Gebre AK, Seo J, et al. A novel role for ABCA1-generated large prebeta migrating nascent HDL in the regulation of hepatic VLDL triglyceride secretion. J Lipid Res 2010; 51:729-742.
12. Brown AM, Gibbons GF. Insulin inhibits the maturation phase of VLDL assembly via a phosphoinositide 3-kinase-mediated event. Arterioscler Thromb Vasc Biol 2001; 21:1656-1661. (Pubitemid 34215587)
13. Sparks JD, Phung TL, Bolognino M, et al. Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wort-mannin in primary cultures of rat hepatocytes. Biochem J 1996; 313:567-574.
14. Mulya A, Lee JY, Gebre AK, et al. Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. J Lipid Res 2008; 49:2390-2401.
15. Wellington CL, Walker EK, Suarez A, et al. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest 2002; 82:273-283. (Pubitemid 34242521)
16. Timmins JM, Lee JY, Boudyguina E, et al. Targeted inactivation of hepatic ABCA1 causes profound hypoalphalipoproteinemia and kidney hypercata-bolism of apoA-I. J Clin Invest 2005; 115:1333-1342. (Pubitemid 40629053)
17. Chung S, Timmins JM, Duong M, et al. Targeted deletion of hepatocyte ABCA1 leads to very low density lipoprotein triglyceride overproduction and low density lipoprotein hypercatabolism. J Biol Chem 2010; 285:12197-12209.
18. Liu M, Chung S, Shelness GS, et al. Hepatic ABCA1 and VLDL triglyceride production. Biochim Biophys Acta 2012. [Epub ahead of print]
19. Greten H, Hannemann T, Gusek W, et al. Lipoproteins and lipolytic plasma enzymes in a case of Tangier disease. N Engl J Med 1974; 291:548-552.
20. Feng Y, Lievens J, Jacobs F, et al. Hepatocyte-specific ABCA1 transfer increases HDL cholesterol but impairs HDL function and accelerates atherosclerosis. Cardiovasc Res 2010; 88:376-385.
21. Joyce CW, Amar MJ, Lambert G, et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci USA 2002; 99:407-412. (Pubitemid 34060374)
22. Wellington CL, Brunham LR, Zhou S, et al. Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. J Lipid Res 2003; 44:1470-1480. (Pubitemid 37279591)
23. Singaraja RR, Bocher V, James ER, et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-depen-dent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem 2001; 276:33969-33979.
24. Joyce CW, Wagner EM, Basso F, et al. ABCA1 Overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis. J Biol Chem 2006; 281:33053-33065. (Pubitemid 46036688)
25. Moore KJ, Rayner KJ, Suarez Y, et al. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu Rev Nutr 2011; 31:49-63.
26. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109:1125-1131. (Pubitemid 34496588)
27. Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011; 121:2921-2931.
28. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in nonhuman primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478:404-407.
29. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466:707-713.
30. Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res 2011; 52:189-206.
31. Zhang Z, Tao L, Chen Z, et al. Association of genetic loci with blood lipids in the Chinese population. PLoS One 2011; 6:e27305.
32. Delgado-Lista J, Perez-Martinez P, Perez-Jimenez F, et al. ABCA1 gene variants regulate postprandial lipid metabolism in healthy men. Arterioscler Thromb Vasc Biol 2010; 30:1051-1057.
33. Brown MS, Ye J, Goldstein JL. HDL miR-ed down by SREBP introns. Science 2010; 328:1495-1496.